SIHUAN PHARM (00460): The injectable polycaprolactone microsphere facial filler and injectable sodium hyaluronate composite solution independently developed by Meiyan Space have been approved for marketing in Hong Kong.

SIHUAN PHARM (00460) announces that recently, the injectable polycaprolactone microsphere facial filler (PCL) and injectable sodium hyaluronate composite solution (FL) (skin booster), independently developed and produced by Meiyan Space Biotechnology (Jilin) Co., Ltd. (Meiyan Space), a subsidiary of the group, have successively been approved for marketing in the Hong Kong Special Administrative Region of China. The approved specifications of the injectable polycaprolactone microsphere facial filler include 0.5mL/vial, 1.0mL/vial, and 2.0mL/vial; the approved specifications of the injectable sodium hyaluronate composite solution include 0.5mL/vial, 1.0mL/vial, 1.5mL/vial, 2.0mL/vial, 2.5mL/vial, 3.0mL/vial, and 5mL/box (containing 2 units of 2.5mL/vial specification products). The announcement states that expanding into international markets is one of the important strategies of the company's medical aesthetics business, and this year is a year of accelerated overseas layout. PCL is a regenerative filler product, and the skin booster is a skin quality maintenance product, both of which are mainstream categories in the light medical aesthetics field and have achieved good sales and market response after being launched in mainland China. The approval and marketing of these two self-developed products in Hong Kong not only expands the market space of the two products, but also marks a breakthrough in the registration of the group's medical aesthetics products in the Hong Kong region, laying a solid foundation for the group to deeply cultivate the Hong Kong market and radiate to the Asia-Pacific region, and helping the group move toward the long-term development goal of becoming an international medical aesthetics enterprise. At the same time, this approval also verifies that the R&D, production, and quality management systems of the group's medical aesthetics products comply with the regulatory requirements of the Hong Kong region, accumulating valuable practical experience for the group's subsequent global multi-regional registration and certification of multiple self-developed medical aesthetics products, and continuously consolidating the foundation for the global development of the medical aesthetics segment.